IngentaConnect Safety and Tolerability of Once Versus Twice Daily Atomoxetine in...

Authors: Adler, Lenard¹; Dietrich, Anthony²; Reimherr, Fred³; Taylor, Leslie⁴; Sutton, Virginia⁵; Bakken, Rosalie⁵; Allen, Albert⁵; Kelsey, Douglas⁵

Source: Annals of Clinical Psychiatry (after Jan 1, 2004), Volume 18, Number 2, April-June 2006 , pp. 107-113(7)

Publisher: Taylor and Francis Ltd

Abstract:

Background. Attention-Deficit/Hyperactivity Disorder (ADHD) is a disorder characterized by hyperactivity, impulsiveness, and inattention that affects 4% of adults. Atomoxetine hydrochloride is an FDA-approved treatment for adult ADHD, but no studies have clarified whether there are advantages to once versus twice daily dosing. Methods. This randomized, double-blind, multicenter study compared safety and tolerability of 80 mg atomoxetine QD versus 40 mg atomoxetine BID in 218 adults with ADHD. Treatment-emergent adverse events (TEAEs), laboratory values, vital signs, weight, electrocardiograms, scores on the Arizona Sexual Experiences Scale, and efficacy (using the Conners' ADHD Rating Scale-Investigator Rated: Screening Version) were assessed. Results. The overall incidence for any one TEAE was low. There was no significant treatment group difference in likelihood of patients experiencing ≥1 of the four most commonly observed TEAEs (dry mouth, insomnia, nausea, and erectile dysfunction). Frequency of nausea was significantly lower in the 40 mg BID group (16.4%) than the 80 mg QD group (32.4%; p = .007). There were no unexpected safety results. Although both QD and BID treatments were efficacious, the reduction in scores was greater for BID treatment. Conclusions. Data indicate both dosing strategies are safe, well tolerated, and efficacious in the treatment of adult ADHD. Changes in dosing strategy are unlikely to be accompanied by safety risks, implying that there is room for prescribers to use discretion and to base dosing strategies on individual factors.

Keywords: attention-deficit/hyperactivity disorder; atomoxetine; nonstimulants; adults

Document Type: Research article

DOI: 10.1080/10401230600614603

Affiliations: 1: School of Medicine, New York University, New York, NY, USA 2: Neuropsychiatric Associates, Woodstock, VT, USA 3: Mood Disorders Clinic, Department of Psychiatry, University of Utah Health Sciences Center, Salt Lake City, UT, USA 4: Dean Foundation, Middleton, WI, USA 5: Lilly Research Laboratories, Indianapolis, IN, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$45.09 plus tax

Safety and Tolerability of Once Versus Twice Daily Atomoxetine in Adults with ADHD